Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

13. November 2026 aktualisiert von: Pfizer

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.

This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.

All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

268

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • San Juan, Puerto Rico, 00935
        • Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office
    • Arkansas
      • Fayetteville, Arkansas, Vereinigte Staaten, 72703
        • Highlands Oncology Group, PA
      • Rogers, Arkansas, Vereinigte Staaten, 72758
        • Highlands Oncology Group, PA
      • Springdale, Arkansas, Vereinigte Staaten, 72762
        • Highlands Oncology Group, PA
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49546
        • START Midwest, LLC

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • 18 years of age or older
  • Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
  • PIK3CA mutation
  • Archived tumor specimen or fresh tumor biopsy
  • Measurable disease
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Active or clinically significant dermatologic conditions
  • Active malignancy within 3 years prior to enrollment
  • Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
  • Major surgery or radiation therapy within 3 weeks prior to study entry
  • Prior irradiation to >25% of the bone marrow
  • Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
  • Unmanageable ascites
  • Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
  • Renal impairment
  • Hepatic dysfunction
  • Hematologic abnormalities
  • Uncontrolled diabetes
  • Cardiac abnormalities
  • Active or history of clinically significant GI or inflammatory GI disease
  • Other unacceptable abnormalities or prohibited therapies as defined by protocol

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part 1 Dose Escalation Cohort 1A

PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug

Taken by mouth (PO)

Experimental: Part 1 Dose Escalation Cohort 1B

Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

Andere Namen:
  • Faslodex

Taken by mouth (PO)

Experimental: Part 1 Dose Escalation Cohort 1C

Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

Andere Namen:
  • Faslodex

Taken by mouth (PO)

Selective CDK4 inhibitor

Andere Namen:
  • PF-07220060
Experimental: Part 1 Dose Escalation Cohort 1D

Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug

Monoclonal antibody (EGFR inhibitor)

Andere Namen:
  • Erbitux

Taken by mouth (PO)

Experimental: Part 2 Dose Optimization/Expansion Cohort 2A

Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug

Taken by mouth (PO)

Selective CDK4 inhibitor

Andere Namen:
  • PF-07220060

Nonsteroidal aromatase inhibitor

Andere Namen:
  • Femara

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
Zeitfenster: Baseline up to 28 days

Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

Baseline up to 28 days
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
Zeitfenster: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
Zeitfenster: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Objective Response Rate (ORR)
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
Zeitfenster: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
Zeitfenster: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

TTR is defined as the time from start date of treatment to first documentation of CR or PR.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 2: Overall Survival (OS)
Zeitfenster: Up to approximately 2 years

OS is defined as time from from start date of treatment to the date of death due to any cause

Up to approximately 2 years
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Cmax
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Cmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Tmax
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Tmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on AUClast
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on AUClast of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
Zeitfenster: Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the pre- and post-dose concentrations of PF-08165784

Baseline through end of Cycle 1 (each cycle is 28 days)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Pfizer CT.gov Call Center, Pfizer

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

9. November 2026

Primärer Abschluss (Geschätzt)

22. März 2030

Studienabschluss (Geschätzt)

21. März 2032

Studienanmeldedaten

Zuerst eingereicht

20. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Oktober 2026

Zuerst gepostet (Tatsächlich)

27. Oktober 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren